광선각화증 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 치료법별, 약제클래스별, 최종사용자별, 지역별, 경쟁별 세분화(2020-2030년)
Actinic Keratosis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy, By Drug Class, By End User, By Region and Competition, 2020-2030F
상품코드:1886416
리서치사:TechSci Research
발행일:2025년 12월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 광선각화증 치료 시장은 2024년 69억 2,000만 달러에서 2030년까지 92억 5,000만 달러로, CAGR 4.95%로 성장할 것으로 예측됩니다. 세계 광선각화증(AK) 치료 시장은 주로 만성적인 자외선 노출에 의해 유발되는 전암성 피부 병변을 치료하기 위한 외용제 및 광역학 치료와 같은 약물 요법과 냉동 요법 및 외과적 절제술과 같은 치료적 접근법을 포함합니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
69억 2,000만 달러
시장 규모 : 2030년
92억 5,000만 달러
CAGR : 2025-2030년
4.95%
가장 빠르게 성장하는 부문
외과수술
최대 시장
북미
주요 시장 성장 촉진요인
세계 광선각화증 치료 시장은 광선각화증 유병률 증가와 전 세계 고령화에 의해 크게 견인되고 있습니다. 광선각화증 발생률 증가는 진단 및 치료적 개입이 필요한 환자층을 직접적으로 확대합니다.
주요 시장 과제
숙련된 피부과 전문의와 자격을 갖춘 의료진의 지속적인 부족은 세계 광선각화증 치료제 시장의 성장을 크게 저해하고 있습니다. 이 부족은 치료의 보급을 직접적으로 제한하고, 환자 치료에 큰 지연을 초래하고 있습니다.
주요 시장 동향
새로운 외용제 및 전신 치료제의 등장은 효능 향상, 부작용 감소, 혁신적인 작용기전을 가진 첨단 약물의 도입으로 세계 광선각화증 치료제 시장을 크게 견인하고 있습니다. 이러한 새로운 치료법은 기존 치료법의 한계를 해결하는 경우가 많으며, 피부과 의사에게 환자 맞춤형 치료를 위한 폭넓은 선택권과 잠재적으로 높은 치료율을 제공합니다.
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 세계의 광선각화증 치료 시장 전망
시장 규모·예측
금액별
시장 점유율·예측
치료법별(외용 요법, 외과수술, 광역학요법)
약제클래스별(뉴클레오티드 대사 저해제, NSAIDs, 면역 반응 수식제, 광증감제, 기타)
최종사용자별(병원·진료소, 외래 진료 센터, 기타)
지역별
기업별(2024)
시장 맵
제6장 북미의 광선각화증 치료 시장 전망
시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 광선각화증 치료 시장 전망
시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 광선각화증 치료 시장 전망
시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 광선각화증 치료 시장 전망
시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
남아프리카공화국
제10장 남미의 광선각화증 치료 시장 전망
시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
촉진요인
과제
제12장 시장 동향과 발전
합병·인수
제품 출시
최근 동향
제13장 세계의 광선각화증 치료 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Almirall S.A.
LEO Pharma A/S
Sun Pharmaceutical Industries Ltd.
Novartis AG
GALDERMA SA
Ortho Dermatologics(Bausch Health Companies Inc.)
BIOFRONTERA AG
Hill Dermaceuticals, Inc.
제16장 전략적 제안
제17장 조사회사 소개·면책사항
KSA
영문 목차
영문목차
The Global Actinic Keratosis Treatment Market will grow from USD 6.92 Billion in 2024 to USD 9.25 Billion by 2030 at a 4.95% CAGR. The global actinic keratosis (AK) treatment market encompasses pharmaceutical interventions, such as topical medications and photodynamic therapy, alongside procedural approaches like cryotherapy and surgical excision, all aimed at addressing precancerous skin lesions primarily induced by chronic ultraviolet exposure.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 6.92 Billion
Market Size 2030
USD 9.25 Billion
CAGR 2025-2030
4.95%
Fastest Growing Segment
Surgery
Largest Market
North America
Key Market Drivers
The global actinic keratosis treatment market is significantly propelled by the rising prevalence of actinic keratosis and the aging global population. The increasing incidence of actinic keratosis directly expands the patient pool requiring diagnosis and therapeutic intervention. According to the British Journal of Dermatology, March 2024, in "Global epidemiology of actinic keratosis in the general population: a systematic review and meta-analysis", the global prevalence rate for actinic keratosis is 14%, indicating a substantial disease burden worldwide.
Key Market Challenges
The persistent lack of skilled dermatology specialists and qualified healthcare providers significantly impedes the growth of the global actinic keratosis treatment market. This shortage directly limits treatment penetration and causes substantial delays in patient care. Across various regions, the inadequate availability of specialists means fewer individuals receive timely diagnosis and appropriate therapeutic interventions for precancerous skin lesions.
Key Market Trends
The emergence of novel topical and systemic therapies significantly drives the global actinic keratosis treatment market by introducing advanced agents with improved efficacy, reduced side effects, and innovative mechanisms of action. These new treatments often address limitations of existing options, providing dermatologists with a broader range of choices for tailored patient care and potentially higher clearance rates.
Key Market Players
Almirall S.A.
LEO Pharma A/S
Sun Pharmaceutical Industries Ltd.
Novartis AG
GALDERMA SA
Ortho Dermatologics (Bausch Health Companies Inc.)
BIOFRONTERA AG
Hill Dermaceuticals, Inc.
Report Scope:
In this report, the Global Actinic Keratosis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Actinic Keratosis Treatment Market, By Therapy:
Topical
Surgery
Photodynamic Therapy
Actinic Keratosis Treatment Market, By Drug Class:
Nucleoside metabolic inhibitor
NSAIDS
Immune response modifiers
Photoenhancers
Others
Actinic Keratosis Treatment Market, By End User:
Hospitals & Clinics
Ambulatory Care Centers
Others
Actinic Keratosis Treatment Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Actinic Keratosis Treatment Market.
Available Customizations:
Global Actinic Keratosis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Actinic Keratosis Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapy (Topical, Surgery, Photodynamic Therapy)
5.2.2. By Drug Class (Nucleoside metabolic inhibitor, NSAIDS, Immune response modifiers, Photoenhancers, Others)
5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Actinic Keratosis Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapy
6.2.2. By Drug Class
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Actinic Keratosis Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapy
6.3.1.2.2. By Drug Class
6.3.1.2.3. By End User
6.3.2. Canada Actinic Keratosis Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapy
6.3.2.2.2. By Drug Class
6.3.2.2.3. By End User
6.3.3. Mexico Actinic Keratosis Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapy
6.3.3.2.2. By Drug Class
6.3.3.2.3. By End User
7. Europe Actinic Keratosis Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy
7.2.2. By Drug Class
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Actinic Keratosis Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapy
7.3.1.2.2. By Drug Class
7.3.1.2.3. By End User
7.3.2. France Actinic Keratosis Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapy
7.3.2.2.2. By Drug Class
7.3.2.2.3. By End User
7.3.3. United Kingdom Actinic Keratosis Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapy
7.3.3.2.2. By Drug Class
7.3.3.2.3. By End User
7.3.4. Italy Actinic Keratosis Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapy
7.3.4.2.2. By Drug Class
7.3.4.2.3. By End User
7.3.5. Spain Actinic Keratosis Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapy
7.3.5.2.2. By Drug Class
7.3.5.2.3. By End User
8. Asia Pacific Actinic Keratosis Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy
8.2.2. By Drug Class
8.2.3. By End User
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Actinic Keratosis Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapy
8.3.1.2.2. By Drug Class
8.3.1.2.3. By End User
8.3.2. India Actinic Keratosis Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapy
8.3.2.2.2. By Drug Class
8.3.2.2.3. By End User
8.3.3. Japan Actinic Keratosis Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapy
8.3.3.2.2. By Drug Class
8.3.3.2.3. By End User
8.3.4. South Korea Actinic Keratosis Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapy
8.3.4.2.2. By Drug Class
8.3.4.2.3. By End User
8.3.5. Australia Actinic Keratosis Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapy
8.3.5.2.2. By Drug Class
8.3.5.2.3. By End User
9. Middle East & Africa Actinic Keratosis Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy
9.2.2. By Drug Class
9.2.3. By End User
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Actinic Keratosis Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapy
9.3.1.2.2. By Drug Class
9.3.1.2.3. By End User
9.3.2. UAE Actinic Keratosis Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapy
9.3.2.2.2. By Drug Class
9.3.2.2.3. By End User
9.3.3. South Africa Actinic Keratosis Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapy
9.3.3.2.2. By Drug Class
9.3.3.2.3. By End User
10. South America Actinic Keratosis Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapy
10.2.2. By Drug Class
10.2.3. By End User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Actinic Keratosis Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapy
10.3.1.2.2. By Drug Class
10.3.1.2.3. By End User
10.3.2. Colombia Actinic Keratosis Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapy
10.3.2.2.2. By Drug Class
10.3.2.2.3. By End User
10.3.3. Argentina Actinic Keratosis Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapy
10.3.3.2.2. By Drug Class
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Actinic Keratosis Treatment Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Almirall S.A.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. LEO Pharma A/S
15.3. Sun Pharmaceutical Industries Ltd.
15.4. Novartis AG
15.5. GALDERMA SA
15.6. Ortho Dermatologics (Bausch Health Companies Inc.)
